About
Swipp develops orally dissolving buccal films containing midazolam for the treatment of acute epileptic seizures, focusing on faster drug uptake and easier administration for patients and caregivers. Their approach uses well-established drug substances to shorten development times, aiming to reach first clinical trials within about three years.
Explore Swipp's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.